Share on LinkedInShare on LinkedIn

ARTICLE · 30 SEPTEMBER 2020

When Are Recombinant Proteins Structurally Different Than Their Natural Counterparts?

The answer to this question was central to the remand for a new trial on a judgement as a matter of law (JMOL) decision from the District Court overturning the jury verdict of anticipation in the...

United StatesIntellectual Property

The answer to this question was central to the remand for a new trial on a judgement as a matter of law (JMOL) decision from the District Court overturning the jury verdict of anticipation in the Federal Circuit's September 28, 2020 decision in Biogen MA Inc. v EMD Serono, Inv. Pfizer Inc. See http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1133.OPINION.9-28-2020_1659873.pdf.

Biogen asserted their U.S. 7,588,755 against EMD Serono and Pfizer for patent infringement by the product Rebif, a recombinant interferon-β product used for treating Multiple Sclerosis. Bayer and Novartis were also initially part of the suit but the actions were severed from the issues in the appeal (fn 1).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from